New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 10mg - capsule - 10 mg - active: lenalidomide 10mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose sunset yellow fcf tartrazine titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 15mg - capsule - 15 mg - active: lenalidomide 15mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose tartrazine titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: allura red ac brilliant blue fcf croscarmellose sodium erythrosine gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 20mg - capsule - 20 mg - active: lenalidomide 20mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.